New Delhi: Amidst the increasing threat of the Omicron variant of Covid-19, a big decision can be taken on Bharat Biotech’s Nasal Vaccine. In fact, the Subject Expert Committee (SEC) of the Drugs Controller General of India (DCGI) is going to have a big meeting on this issue. In the meeting, the SEC will consider whether Bharat Biotech’s nasal vaccine can be used as a booster dose. sources learned that Bharat Biotech has proposed to use its nasal vaccine as a booster dose. This booster dose will be given to those who have previously taken the vaccine of Covishield or Cowaxin.
According to sources, the meeting of the SEC can be held on Tuesday afternoon. In fact, in its application, Bharat Biotech has proposed to use its nasal vaccine BBV154 as a booster dose in already vaccinated people. Bharat Biotech aims that the clinical trial of this vaccine will be done on 2.5 thousand such people who have taken Kovishield. And it will be done on two and a half thousand such people who have taken Cowaxin earlier.
Was told safe on children
Earlier, Bharat Biotech International Limited (BBIL) had announced that Covaxin (BBV152) manufactured by it, its full-virus inactivated COVID-19 vaccine candidate, has proven to be safe, well-tolerated in pediatric subjects. Qualified and immunogenic. For this, the second and third phases were studied.
A press release from the vaccine manufacturer said that Bharat Biotech had evaluated the safety, reactivity, and immunogenicity of Covaxin in healthy children and adolescents aged 2-18 years. To do this, open-label and multicenter studies were conducted in the second and third phases.
WHO had advised booster dose
In early December, the World Health Organization’s Strategic Advisory Group of Experts on Immunization stated that people who are immunocompromised or who have received an inactivated COVID-19 vaccine may experience a decrease in antibodies and an increased number of COVID-19 cases due to the new variant Omicron. In view of covid-19 cases, booster shots should be taken for safety.
